News on in vitro diagnostics for gastrointestinal disease.

Exalenz's systems, the BreathID Hp point-of-care system and the BreathID Hp Lab system, were previously cleared by the FDA for use in detecting H. pylori infection in adults.

The tests detect Campylobacter jejuni and Campylobacter coli and improve upon currently available immunoassays and culture tests, the firm said.

Researchers at Cincinnati Children's Hospital have identified markers for earlier detection of the condition, for which patient outcomes hinge on rapid action.

The company said it will use the proceeds to accelerate development of its gastrointestinal platform, including diagnostics and therapeutics for the GI tract.

The firm said that a number of hospitals and labs are expected to evaluate the panel, presenting it with about a $2.0 million annual revenue opportunity.